Conivaptan and its role in the treatment of hyponatremia
Jalal K Ghali,1 Jareer O Farah,2 Suleiman Daifallah,3 Hassan A Zabalawi,4 Hammam D Zmily51Detroit Medical Center, Detroit, MI, USA; 2Wayne State University/Detroit Medical Center, Detroit, MI, USA; 3John D Dingell VA Medical Center, Detroit, MI, USA; 4,5Wayne State University/Detroit Medical Center,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-10-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | http://www.dovepress.com/conivaptan-and-its-role-in-the-treatment-of-hyponatremia-a3638 |
| _version_ | 1818445112586272768 |
|---|---|
| author | Jalal K Ghali Jareer O Farah Suleiman Daifallah et al |
| author_facet | Jalal K Ghali Jareer O Farah Suleiman Daifallah et al |
| author_sort | Jalal K Ghali |
| collection | DOAJ |
| description | Jalal K Ghali,1 Jareer O Farah,2 Suleiman Daifallah,3 Hassan A Zabalawi,4 Hammam D Zmily51Detroit Medical Center, Detroit, MI, USA; 2Wayne State University/Detroit Medical Center, Detroit, MI, USA; 3John D Dingell VA Medical Center, Detroit, MI, USA; 4,5Wayne State University/Detroit Medical Center, Detroit, MI, USAAbstract: Hyponatremia is the most common electrolyte abnormality in hospitalized patients and is associated with increased morbidity and mortality. The recognition of the central role that arginin vasopressin plays in the pathogenesis of hyponatremia and the discovery that its actions are mediated by stimulation of V1A and V2 receptors have led to the development of a new class of drugs, the arginin vasopressin antagonists. Conivaptan is a nonselective V1A and V2 receptors antagonist that was the first of this class to be approved by the FDA for the management of euvolemic and hypervolemic hyponatremia. Its short-term safety and efficacy for the correction of hyponatremia have been established by multiple double-blind, randomized, controlled studies. Blocking the effects of arginin vasopressin on V2 receptors produces aquaresis – the electrolyte-sparing excretion of water – an ideal approach to correct hypervolemic hyponatremia. The nonselectivity of conivaptan offers a theoretical advantage for its use in heart failure that may merit further exploration.Keywords: arginine vasopressin antagonist, conivaptan, heart failure, hyponatremia  |
| first_indexed | 2024-12-14T19:26:39Z |
| format | Article |
| id | doaj.art-6e43de08019a45e6b00f1669f393bfab |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-14T19:26:39Z |
| publishDate | 2009-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-6e43de08019a45e6b00f1669f393bfab2022-12-21T22:50:11ZengDove Medical PressDrug Design, Development and Therapy1177-88812009-10-012009default253268Conivaptan and its role in the treatment of hyponatremiaJalal K GhaliJareer O FarahSuleiman Daifallahet alJalal K Ghali,1 Jareer O Farah,2 Suleiman Daifallah,3 Hassan A Zabalawi,4 Hammam D Zmily51Detroit Medical Center, Detroit, MI, USA; 2Wayne State University/Detroit Medical Center, Detroit, MI, USA; 3John D Dingell VA Medical Center, Detroit, MI, USA; 4,5Wayne State University/Detroit Medical Center, Detroit, MI, USAAbstract: Hyponatremia is the most common electrolyte abnormality in hospitalized patients and is associated with increased morbidity and mortality. The recognition of the central role that arginin vasopressin plays in the pathogenesis of hyponatremia and the discovery that its actions are mediated by stimulation of V1A and V2 receptors have led to the development of a new class of drugs, the arginin vasopressin antagonists. Conivaptan is a nonselective V1A and V2 receptors antagonist that was the first of this class to be approved by the FDA for the management of euvolemic and hypervolemic hyponatremia. Its short-term safety and efficacy for the correction of hyponatremia have been established by multiple double-blind, randomized, controlled studies. Blocking the effects of arginin vasopressin on V2 receptors produces aquaresis – the electrolyte-sparing excretion of water – an ideal approach to correct hypervolemic hyponatremia. The nonselectivity of conivaptan offers a theoretical advantage for its use in heart failure that may merit further exploration.Keywords: arginine vasopressin antagonist, conivaptan, heart failure, hyponatremia http://www.dovepress.com/conivaptan-and-its-role-in-the-treatment-of-hyponatremia-a3638 |
| spellingShingle | Jalal K Ghali Jareer O Farah Suleiman Daifallah et al Conivaptan and its role in the treatment of hyponatremia Drug Design, Development and Therapy |
| title | Conivaptan and its role in the treatment of hyponatremia |
| title_full | Conivaptan and its role in the treatment of hyponatremia |
| title_fullStr | Conivaptan and its role in the treatment of hyponatremia |
| title_full_unstemmed | Conivaptan and its role in the treatment of hyponatremia |
| title_short | Conivaptan and its role in the treatment of hyponatremia |
| title_sort | conivaptan and its role in the treatment of hyponatremia |
| url | http://www.dovepress.com/conivaptan-and-its-role-in-the-treatment-of-hyponatremia-a3638 |
| work_keys_str_mv | AT jalalkghali conivaptananditsroleinthetreatmentofhyponatremia AT jareerofarah conivaptananditsroleinthetreatmentofhyponatremia AT suleimandaifallah conivaptananditsroleinthetreatmentofhyponatremia AT etal conivaptananditsroleinthetreatmentofhyponatremia |